NASDAQ:KROS

Keros Therapeutics Stock News

Healthcare > Biotechnology

Buy KROS

*Your capital is at risk

$11.15

+0.500 (+4.69%)

At Close: Aug 07, 2026

Investors who lost money on Keros Therapeutics, Inc. should contact Levi & Korsinsky about an ongoing investigation - KROS

07:25am, Monday, 30'th Dec 2024

NEW YORK, NY / ACCESSWIRE / December 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concer

An Investigation Has Commenced on Behalf of Keros Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your KROS Losses

10:30am, Friday, 27'th Dec 2024

NEW YORK, NY / ACCESSWIRE / December 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concer

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Keros Therapeutics, Inc. (KROS) And Encourages Shareholders to Reach Out

10:00am, Friday, 27'th Dec 2024

NEW YORK, NY / ACCESSWIRE / December 27, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company") (NAS

Shareholder Rights Advocates at Levi & Korsinsky Investigate Keros Therapeutics, Inc. (KROS) Regarding Possible Securities Fraud Violations

03:30pm, Thursday, 26'th Dec 2024

NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concer

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Keros Therapeutics, Inc. - KROS

03:00pm, Thursday, 26'th Dec 2024

NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS). Such investors are

An Investigation Has Commenced on Behalf of Keros Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your KROS Losses

10:45am, Thursday, 26'th Dec 2024

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Shareholders to Learn More About the Investigation

10:00am, Thursday, 26'th Dec 2024

NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company") (NAS

Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

10:00am, Thursday, 26'th Dec 2024

Levi & Korsinsky Reminds Keros Therapeutics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - KROS

07:30am, Thursday, 26'th Dec 2024

Lost Money on Keros Therapeutics, Inc. (KROS)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

02:45pm, Tuesday, 24'th Dec 2024

NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concer

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Keros Therapeutics, Inc. - KROS

02:30pm, Tuesday, 24'th Dec 2024

NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS). Such investors are

Lost Money on Keros Therapeutics, Inc.(KROS)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky

10:15am, Tuesday, 24'th Dec 2024

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Shareholders to Inquire about Securities Investigation

10:00am, Tuesday, 24'th Dec 2024

NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company") (NAS

ATTENTION Keros Therapeutics, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights

10:15am, Monday, 23'rd Dec 2024

NEW YORK, NY / ACCESSWIRE / December 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concer

Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Investors to Connect

10:00am, Monday, 23'rd Dec 2024

NEW YORK, NY / ACCESSWIRE / December 23, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company") (NAS

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by